Topics

Regeneron therapy halves LDL cholesterol levels in rare genetic condition

06:40 EDT 15 Aug 2019 | Pharmafile

Regeneron has reported a strong showing for its investigational angiopoietin-like 3 (ANGPTL3) antibody evinacumab in the treatment of the rare genetic condition homozygous familial hypercholesterolemia (HoFH), showing that the therapy met its primary endpoint.

The trial examined the efficacy of evinacumab in patients who, despite treatment with other lipid-lowering therapies including maximally-tolerated statins, PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, ezetimibe, LDL apheresis and lomitapide, had an average LDL cholesterol level of 255mg/dl.

read more

Original Article: Regeneron therapy halves LDL cholesterol levels in rare genetic condition

NEXT ARTICLE

More From BioPortfolio on "Regeneron therapy halves LDL cholesterol levels in rare genetic condition"

Quick Search

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...